Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 8/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | PYGB | P11216 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15962117 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL14380049 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL12899675 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL14732694 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL12929221 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL13068778 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL18501144 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL24107709 | 0.94 | PYGB (0.42) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL12210250 | 0.94 | PYGB (0.42) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL16126880 | 0.94 | PYGB (0.42) | LGALS8OGAPYGBLGALS1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023135229-A1 | GLYCOSIDE HYDROLASE AND/OR TRANSGLYCOSYLASE FOR SYNTHESIS OF XYLOSE OLIGOSACCHARIDES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-07-20 | — | — | WO | disclosed |
| US-8067555-B2 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2011-11-29 | — | — | US | disclosed |
| US-7781416-B2 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | SIGMA-TAU RESEARCH SWITZERLAND S.A. (CH) | 2010-08-24 | — | — | US | disclosed |
| US-20080139503-A1 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-06-12 | — | — | US | disclosed |
| US-20080051567-A1 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | SIGMA-TAU INDUSTRIE FARMACEUTICHERIUNITE S.P.A. (IT) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139503-A1 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | HPSE, SERPINC1, PLAUR | LGALS8 556/4885OGA 411/4885PYGB 1065/4885 |
| US-20080051567-A1 | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect | HPSE, SERPINC1, PLAUR | LGALS8 556/4885OGA 411/4885PYGB 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.